The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Hepatitis C virus resistance to protease inhibitors
Open accessAbstract
Recent advances in molecular biology have led to the development of novel small molecules that target specific viral proteins of the hepatitis C virus (HCV) life cycle. These drugs, collectively termed directly acting antivirals (DAA) against HCV, include a range of non-structural (NS) 3/NS4A protease, NS5B polymerase, and NS5A inhibitors at various stages of clinical development. The rapid replication rate of HCV, along with the low fidelity of its polymerase, gives rise to generations of mutations throughout the viral genome resulting in remarkable sequence variation in the HCV population, known as a quasispecies. The efficacy of DAAs is limited by the presence of those mutations that give rise to amino-acid substitutions within the targeted protein, and that affect the viral sensitivity to these compounds. Thus, due to the high genetic variability of HCV, variants with reduced susceptibility to DAA can occur naturally even before treatment begins, but usually at low levels. Not surprisingly then, these changes are selected in patients either breaking through or not responding to potent DAA treatment. In vitro or in vivo, six major position mutations in the NS3 HCV protease (36, 54, 155, 156, 168, and 170) have now been reported associated with different levels of resistance. The amino acid composition at several of the drug resistance sites can vary between the HCV genotypes/subtypes, resulting in different consensus amino acids leading to a reduction in replicative fitness as well as reduced DAA sensitivity. Different amino acid diversity profiles for HCV genotypes/subtypes suggest differences in the position/type of immune escape and drug resistance mutations. Also, different pathways of resistance profiles based on the chemical scaffold (linear or macrocyclic) of the protease inhibitors have been described. This review first describes how resistance to a protease inhibitor can develop and then provides an overview of the mechanism of how particular mutations confer varying levels of resistance to protease inhibitor, which have been identified and characterized using both genotypic and phenotypic tools. Future potential therapeutic strategies to assist patients who do develop resistance to protease inhibitors are also outlined. The challenge developing new HCV protease inhibitors should take into consideration not only the antiviral potency of the drugs, the occurrence and importance of side effects, the frequency of oral administration, but also the resistance profiles of these agents.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance
Ge, D., Fellay, J., Thompson, A. J., Simon, J. S., Shianna, K. V., Urban, T. J., Heinzen, E. L., Qiu, P., Bertelsen, A. H., Muir, A. J., et al. (2009) · Nature · doi:10.1038/nature08309 · Cited by 3,514
Singh, R. P., Kurz, J., & Boiteau, G. (1996) · Journal of Virological Methods · doi:10.1016/0166-0934(96)02096-4 · Cited by 2,552
Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus
Meylan, E., Curran, J., Hofmann, K., Moradpour, D., Binder, M., Bartenschlager, R., & Tschopp, J. (2005) · Nature · doi:10.1038/nature04193 · Cited by 2,401
Siliciano, J. D., Kajdas, J., Finzi, D., Quinn, T. C., Chadwick, K., Margolick, J. B., Kovacs, C., Gange, S. J., & Siliciano, R. F. (2003) · Nature Medicine · doi:10.1038/nm880 · Cited by 1,703
Consensus Proposals for a Unified System of Nomenclature of Hepatitis C Virus Genotypes *
Simmonds, P., Bukh, J., Combet, C., Deléage, G., Enomoto, N., Feinstone, S., Halfon, P., Inchauspé, G., Kuiken, C., Maertens, G., et al. (2005) · Hepatology · doi:10.1002/hep.20819 · Cited by 1,516
Self-citationLi, K., Foy, E., Ferreon, J. C., Nakamura, M., Ferreon, A. C. M., Ikeda, M., Ray, S. C., Gale, M., & Lemon, S. M. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0408824102 · Cited by 1,092
Telaprevir with Peginterferon and Ribavirin for Chronic HCV Genotype 1 Infection
McHutchison, J. G., Everson, G. T., Gordon, S. C., Jacobson, I. M., Sulkowski, M., Kauffman, R., McNair, L., Alam, J., & Muir, A. J. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0806104 · Cited by 1,089
Viral dynamics in hepatitis B virus infection.
Nowak, M. A., Bonhoeffer, S., Hill, A. M., Boehme, R., Thomas, H. C., & McDade, H. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.9.4398 · Cited by 1,045
Telaprevir and Peginterferon with or without Ribavirin for Chronic HCV Infection
Hézode, C., Forestier, N., Dusheiko, G., Ferenci, P., Pol, S., Goeser, T., Bronowicki, J.-P., Bourlière, M., Gharakhanian, S., Bengtsson, L., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0807650 · Cited by 1,025
Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect
Gao, M., Nettles, R. E., Belema, M., Snyder, L. B., Nguyen, V. N., Fridell, R. A., Serrano-Wu, M. H., Langley, D. R., Sun, J.-H., O’Boyle II, D. R., et al. (2010) · Nature · doi:10.1038/nature08960 · Cited by 939
An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus
Lamarre, D., Anderson, P. C., Bailey, M., Beaulieu, P., Bolger, G., Bonneau, P., Bös, M., Cameron, D. R., Cartier, M., Cordingley, M. G., et al. (2003) · Nature · doi:10.1038/nature02099 · Cited by 917
Drug-resistance genotyping in HIV-1 therapy: the VIRAD APT randomi sed controlled trial
Durant, J., Clevenbergh, P. A., Halfon, P., Delgiudice, P., Porsin, S., Simonet, P., Montagne, N., Boucher, C. A., Schapiro, J., & Dellamonica, P. (1999) · The Lancet · doi:10.1016/s0140-6736(98)12291-2 · Cited by 752
Self-citationKwo, P. Y., Lawitz, E. J., McCone, J., Schiff, E. R., Vierling, J. M., Pound, D., Davis, M. N., Galati, J. S., Gordon, S. C., Ravendhran, N., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60934-8 · Cited by 704
Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy
Palmer, S., Maldarelli, F., Wiegand, A., Bernstein, B., Hanna, G. J., Brun, S. C., Kempf, D. J., Mellors, J. W., Coffin, J. M., & King, M. S. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0800050105 · Cited by 638
Sarrazin, C., Kieffer, T. L., Bartels, D., Hanzelka, B., Müh, U., Welker, M., Wincheringer, D., Zhou, Y., Chu, H., Lin, C., et al. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.02.037 · Cited by 616
Resistance to Direct Antiviral Agents in Patients With Hepatitis C Virus Infection
Sarrazin, C., & Zeuzem, S. (2010) · Gastroenterology · doi:10.1053/j.gastro.2009.11.055 · Cited by 504
Rapid Emergence of Protease Inhibitor Resistance in Hepatitis C Virus
Rong, L., Dahari, H., Ribeiro, R. M., & Perelson, A. S. (2010) · Science Translational Medicine · doi:10.1126/scitranslmed.3000544 · Cited by 355
Kuntzen, T., Timm, J., Berical, A., Lennon, N., Berlin, A. M., Young, S. K., Lee, B., Heckerman, D., Carlson, J., Reyor, L. L., et al. (2008) · Hepatology · doi:10.1002/hep.22549 · Cited by 349
Retrograde axonal transport: pathways to cell death?
Perlson, E., Maday, S., Fu, M.-M., Moughamian, A. J., & Holzbaur, E. L. F. (2010) · Trends in Neurosciences · doi:10.1016/j.tins.2010.03.006 · Cited by 339
Gane, E. J., Roberts, S. K., Stedman, C. A., Angus, P. W., Ritchie, B., Elston, R., Ipe, D., Morcos, P. N., Baher, L., Najera, I., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61384-0 · Cited by 335
The Hepatitis C Virus Life Cycle as a Target for New Antiviral Therapies
Pawlotsky, J., Chevaliez, S., & McHutchison, J. G. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.116 · Cited by 325
Susser, S., Welsch, C., Wang, Y., Zettler, M., Domingues, F. S., Karey, U., Hughes, E., Ralston, R., Tong, X., Herrmann, E., et al. (2009) · Hepatology · doi:10.1002/hep.23192 · Cited by 318
Expert opinion on the treatment of patients with chronic hepatitis C
Zeuzem, S., Berg, T., Moeller, B., Hinrichsen, H., Mauss, S., Wedemeyer, H., Sarrazin, C., Hueppe, D., Zehnter, E., & Manns, M. P. (2009) · Journal of Viral Hepatitis · doi:10.1111/j.1365-2893.2008.01012.x · Cited by 242
Bartels, D. J., Zhou, Y., Zhang, E. Z., Marcial, M., Byrn, R. A., Pfeiffer, T., Tigges, A. M., Adiwijaya, B. S., Lin, C., Kwong, A. D., et al. (2008) · The Journal of Infectious Diseases · doi:10.1086/591141 · Cited by 211
New Therapies for Hepatitis C Virus Infection
Soriano, V., Peters, M. G., & Zeuzem, S. (2009) · Clinical Infectious Diseases · doi:10.1086/595848 · Cited by 168
McCown, M. F., Rajyaguru, S., Le Pogam, S., Ali, S., Jiang, W.-R., Kang, H., Symons, J., Cammack, N., & Najera, I. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01317-07 · Cited by 164
Viral Determinants of Resistance to Treatment in Patients with Hepatitis C
Wohnsland, A., Hofmann, W. P., & Sarrazin, C. (2007) · Clinical Microbiology Reviews · doi:10.1128/cmr.00010-06 · Cited by 158
Reesink, H. W., Fanning, G. C., Farha, K. A., Weegink, C. J., van Vliet, A., Klooster, G. A. E. V. '., Lenz, O., Aharchi, F., Mariën, K., Remoortere, P. V., et al. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.10.033 · Cited by 155
Quasispecies and its impact on viral hepatitis
Domingo, E., & Gomez, J. (2007) · Virus Research · doi:10.1016/j.virusres.2007.02.001 · Cited by 143
Gaudieri, S., Rauch, A., Pfafferott, K. J., Barnes, E. J., Cheng, W., McCaughan, G. W., Shackel, N. A., Jeffrey, G. P., Mollison, L. C., Baker, R. I., et al. (2008) · Hepatology · doi:10.1002/hep.22773 · Cited by 140
Shimakami, T., Welsch, C., Yamane, D., McGivern, D. R., Yi, M., Zeuzem, S., & Lemon, S. M. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.10.056 · Cited by 133
CARD games between virus and host get a new player
Johnson, C., & Gale, M. (2005) · Trends in Immunology · doi:10.1016/j.it.2005.11.004 · Cited by 128
Viral resistance to specifically targeted antiviral therapies for hepatitis C (STAT-Cs)
Kieffer, T. L., Kwong, A. D., & Picchio, G. (2009) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkp388 · Cited by 116
Rong, L., & Perelson, A. S. (2010) · Critical Reviews in Immunology · doi:10.1615/critrevimmunol.v30.i2.30 · Cited by 108
Nijhuis, M., van Maarseveen, N. M., & Boucher, C. A. (2008) · Handbook of experimental pharmacology · doi:10.1007/978-3-540-79086-0_11 · Cited by 101
Antiviral resistance and specifically targeted therapy for HCV (STAT‐C)
Thompson, A. J. V., & McHutchison, J. G. (2009) · Journal of Viral Hepatitis · doi:10.1111/j.1365-2893.2009.01124.x · Cited by 101
Phenotypic Characterization of Resistant Val36Variants of Hepatitis C Virus NS3-4A Serine Protease
Zhou, Y., Bartels, D. J., Hanzelka, B. L., Müh, U., Wei, Y., Chu, H., Tigges, A. M., Brennan, D. L., Rao, B. G., Swenson, L. L., et al. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00863-07 · Cited by 94
Genetic diversity of the hepatitis C virus: Impact and issues in the antiviral therapy
Guillou‐Guillemette, H. L. (2007) · World Journal of Gastroenterology · doi:10.3748/wjg.v13.i17.2416 · Cited by 93
The impact of drug resistance on the effectiveness of chemotherapy for chronic hepatitis B
Richman, D. D. (2000) · Hepatology · doi:10.1053/jhep.2000.18194 · Cited by 85
Duration and fitness dependence of quasispecies memory
Ruiz-Jarabo, C. M., Arias, A., Molina-París, C., Briones, C., Baranowski, É., Escarmís, C., & Domingo, E. (2002) · Journal of Molecular Biology · doi:10.1006/jmbi.2001.5232 · Cited by 80
Bae, A. S., Sun, S.-C. C., Qi, X., Chen, X., Ku, K. S., Worth, A., Wong, K. A., Harris, J. L., Miller, M. D., & Mo, H. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00777-10 · Cited by 76
Halfon, P., Rifflet, H., Renou, C., Quentin, Y., & Cacoub, P. (2001) · Journal of Clinical Microbiology · doi:10.1128/jcm.39.3.1204-1206.2001 · Cited by 72
Self-citationCubero, M., Esteban, J. I., Otero, T., Sauleda, S., Bes, M., Esteban, R., Guàrdia, J., & Quer, J. (2007) · Virology · doi:10.1016/j.virol.2007.10.006 · Cited by 68
Genetic Barriers to Resistance and Impact on Clinical Response
Luber, A. (2005) · Journal of the International AIDS Society · doi:10.1186/1758-2652-7-3-69 · Cited by 68
Verbinnen, T., Marck, H. G. V., Vandenbroucke, I., Vijgen, L., Claes, M., Lin, T., Simmen, K., Neyts, J. H., Fanning, G. C., & Lenz, O. (2010) · Journal of Virology · doi:10.1128/jvi.01217-10 · Cited by 67
Courcambeck, J., Bouzidi, M., Perbost, R., Jouirou, B., Amrani, N., Cacoub, P., Pèpe, G., Sabatier, J., & Halfon, P. (2006) · Antiviral Therapy · doi:10.1177/135965350601100702 · Cited by 54
Self-citationPreclinical aspects of lamivudine and famciclovir against hepatitis B virus
Shaw, T., & LOCARNINI, S. A. (1999) · Journal of Viral Hepatitis · doi:10.1046/j.1365-2893.1999.00151.x · Cited by 34
Self-citationGenetic and catalytic efficiency structure of an HCV protease quasispecies†
Franco, S., Parera, M., Aparicio, E., Clotet, B., & Martı́nez, M. Á. (2007) · Hepatology · doi:10.1002/hep.21623 · Cited by 33
Cited by
Domingo, E., Sheldon, J., & Perales, C. (2012) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.05023-11 · Cited by 1,009
Ten years of dengue drug discovery: Progress and prospects
Lim, S. P., Wang, Q.-Y., Noble, C. G., Chen, Y.-L., Dong, H., Zou, B., Yokokawa, F., Nilar, S., Smith, P., Beer, D., et al. (2013) · Antiviral Research · doi:10.1016/j.antiviral.2013.09.013 · Cited by 350
Hepatitis C Virus Proteins: From Structure to Function
Moradpour, D., & Penin, F. (2013) · Current Topics in Microbiology and Immunology · doi:10.1007/978-3-642-27340-7_5 · Cited by 301
Metadata
- Authors
- Halfon, P., & Locarnini, S.
- Venue
- Journal of Hepatology
- Publisher
- Elsevier BV
- Published
- 2011-07
- Volume
- 55
- Issue
- 1
- Pages
- 192-206
- ISSN
- 0168-8278 (ISSN-L)
- OpenAlex
- W1989831705
- Cited by
- 305
- References
- 48
- FWCI
- 26.61
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.